# NM_000455.5(STK11):c.702C>T (p.Phe234=)

https://sugi.bio/variant/stk11-p-phe234

## Summary

**STK11 p.Phe234= (c.702C>T)** is classified **Benign/Likely benign** in STK11 (ClinVar, Multiple submitters, 4 submitters; last evaluated 2025-06-06). Absent from gnomAD v4.1; Associated with Peutz-Jeghers syndrome.

**At a glance:** Benign/Likely benign · review: Multiple submitters · rsID rs1555738452 · 4 submitters · 2 linked conditions · absent from gnomAD v4.1

## For patients & families {#patients}

This is a change in the STK11 gene that is classified as benign/likely benign — not considered disease-causing, submitted by 4 submitters, and is linked to Peutz-Jeghers syndrome.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

|  |  |
| --- | --- |
| Typical inheritance (of this condition) | Autosomal dominant |
| Age of onset (of this condition) | Adolescent, Adult, Childhood |
| Prevalence | 1-9 / 100 000 (Worldwide) |
| Clinical trials | 16 registered for this condition — see ClinicalTrials.gov |
| Diagnostic panels | STK11 is a diagnostic-grade gene on 11 Genomics England panels |

**Commonly reported features of Peutz-Jeghers syndrome** (across patients with this condition; presentation varies — frequencies from Orphanet):

- Multiple lentigines — Very frequent (99-80%)
- Gastrointestinal carcinoma — Very frequent (99-80%)
- Abnormality of the gastrointestinal tract — Very frequent (99-80%)
- Macule — Very frequent (99-80%)
- Abnormal pigmentation of the oral mucosa — Very frequent (99-80%)
- Gastrointestinal hemorrhage — Frequent (79-30%)
- Abnormality of the ureter — Occasional (29-5%)
- Abnormality of the nose — Occasional (29-5%)

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0007378/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [STK11](https://sugi.bio/atlas/gene/STK11/) |
| Protein change (HGVS p.) | p.Phe234= |
| Coding change (HGVS c.) | c.702C>T |
| MANE Select transcript | [NM_000455](https://www.ncbi.nlm.nih.gov/nuccore/NM_000455) |
| dbSNP | [rs1555738452](https://www.ncbi.nlm.nih.gov/snp/rs1555738452/) |
| Variant type | single nucleotide variant |
| Location | chr19:1220685-1220685 (GRCh38) |
| ClinVar | [VCV527854](https://www.ncbi.nlm.nih.gov/clinvar/variation/527854/) |

**All HGVS expressions:** `LRG_319:g.36279C>T`, `LRG_319t1:c.702C>T`, `NC_000019.10:g.1220685C>T`, `NC_000019.9:g.1220684C>T`, `NG_007460.2:g.36279C>T`, `NM_000455.5:c.702C>T`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP 1.335, GERP -0.94, phastCons 1 — weakly conserved position
- CADD: **PHRED 14.09**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency: **absent from gnomAD v4.1** — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**STK11** population constraint: LOEUF 0.364, pLI 0.99991, missense-Z 1.4946; ClinGen dosage — haploinsufficiency 3/3, triplosensitivity 0/3. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **Peutz-Jeghers syndrome** — Definitive (AD)
- **familial ovarian cancer** — No Known Disease Relationship (AD)

## Protein context {#protein}

Residue **234** lies in an α-helix; the protein kinase domain.

AlphaFold model confidence (whole protein): pLDDT 79.27, 61% of residues very-high.

**4 experimental structure(s)** (PDB): [2WTK](https://www.rcsb.org/structure/2WTK), [4ZDR](https://www.rcsb.org/structure/4ZDR), [5WXN](https://www.rcsb.org/structure/5WXN), [8VSU](https://www.rcsb.org/structure/8VSU).

## What this gene does {#gene-function}

*Describes the biological roles of STK11 (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** STK11's established molecular role includes magnesium ion binding. p.Phe234= falls in the protein kinase domain.


### Pathways affected {#pathways}

STK11 participates in **4 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [Energy dependent regulation of mTOR by LKB1-AMPK](https://reactome.org/content/detail/R-HSA-380972) | curated |
| [FOXO-mediated transcription of cell death genes](https://reactome.org/content/detail/R-HSA-9614657) | curated |
| [Regulation of TP53 Activity through Phosphorylation](https://reactome.org/content/detail/R-HSA-6804756) | curated |
| [AMPK inhibits chREBP transcriptional activation activity](https://reactome.org/content/detail/R-HSA-163680) | electronic |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** magnesium ion binding, p53 binding, protein serine/threonine kinase activity, ATP binding, protein kinase activator activity.

**Biological process:** protein phosphorylation, protein dephosphorylation, DNA damage response, negative regulation of cell population proliferation, positive regulation of autophagy, peptidyl-threonine phosphorylation.

## Clinical significance {#significance}

**Benign/Likely benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2025-06-06.

**Submitter consensus:** conflicting (2 Likely benign, 1 Likely Benign, 1 Benign).

**Submission history:** 4 submissions (2023–2025); classifications have differed over time.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Labcorp Genetics (formerly Invitae), Labcorp | Likely benign | criteria provided, single submitter | clinical testing | 2025-06-06 |
| All of Us Research Program, National Institutes of Health | Likely Benign | criteria provided, single submitter | clinical testing | 2023-12-13 |
| Ambry Genetics | Likely benign | criteria provided, single submitter | clinical testing | 2024-03-24 |
| Myriad Genetics, Inc. | Benign | criteria provided, single submitter | clinical testing | 2025-03-27 |

## Associated conditions {#conditions}

[Peutz-Jeghers syndrome](https://sugi.bio/atlas/disease/peutz-jeghers-syndrome/), [hereditary neoplastic syndrome](https://sugi.bio/atlas/disease/hereditary-neoplastic-syndrome/).

**Reported phenotype names (ClinVar):** Peutz-Jeghers syndrome, Hereditary cancer-predisposing syndrome, POLYPOSIS, HAMARTOMATOUS INTESTINAL, POLYPS-AND-SPOTS SYNDROME, Peutz-Jeghers polyposis, Periorificial lentiginosis syndrome, Neoplastic Syndromes, Hereditary, Tumor predisposition, Hereditary neoplastic syndrome, Hereditary Cancer Syndrome.

## Similar variants {#similar}

Related STK11 variant pages (same residue, condition, or type): [STK11 p.Phe234Cys](/variant/stk11-p-phe234cys), [STK11 p.Phe234Leu](/variant/stk11-p-phe234leu), [STK11 c.290+1G>A](/variant/stk11-c-290-plus-1g-a), [STK11 c.290+1G>C](/variant/stk11-c-290-plus-1g-c), [STK11 c.290+1G>T](/variant/stk11-c-290-plus-1g-t), [STK11 c.290+2T>A](/variant/stk11-c-290-plus-2t-a), [STK11 c.291-1G>A](/variant/stk11-c-291-minus-1g-a), [STK11 c.291-2A>G](/variant/stk11-c-291-minus-2a-g).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-14); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 527854). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*